Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 18:18 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension
NCT00170950 · Novartis · PHASE3 · terminated · last registry update 2023-10-24 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The study was terminated early because of significant efficacy results for the primary endpoint in favor of benazepril/amlodipine treatment.” | – | Registry record, Novartis |
Also happening at the time. Not shown to be a cause.
No drug target was found for this trial's interventions, so there is no same-target timeline.
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision